Investigators observed that monoclonal antibody ocrelizumab may reduce the risk for upper extremity disability progression in patients with primary progressive multiple sclerosis.
For patients with secondary progressive multiple sclerosis (SPMS), treatment with rituximab is associated with a significantly lower Expanded Disability Status Scale (EDSS) score and delayed progression.
Bafiertam is a new fumarate bioequialent alternative to its prodrug, Tecfidera (dimethyl fumarate; Biogen).
Investigators reviewed patient-reported outcomes to assess treatment satisfaction with teriflunomide and also looked at feedback from physicians regarding the effectiveness of teriflunomide when used in routine clinical practice.
Investigators sought to determine whether absence of lesions in 2 specific brain regions can distinguish Fabry disease from multiple sclerosis.
Researchers evaluated clinical and magnetic resonance imaging data from patients with relapsing-remitting multiple sclerosis treated with alemtuzumab.
Investigators retrospectively reviewed data to compare pregnancy prevalence and complications in women with and without multiple sclerosis.
Investigators assessed presenting symptoms in patients who tested positive for anti-myelin oligodendrocyte glycoprotein.
Investigators conducted a meta-analyses to determine whether injectable IFN-β and glatiramer acetate both decrease the annualized relapse rate and slow disease progression in patients with RRMS.
From 2005 to 2014, trends in palliative care use increased substantially among multiple sclerosis inpatients.
Prevalence of Pediatric Multiple Sclerosis Exceptionally High in Ontario, Canada Compared With Global NumbersDecember 21, 2018
Researchers provide a practical, valid method to estimate the incidence and prevalence of MS in the pediatric population.
Specific locations of cerebral multiple sclerosis lesions appear to be associated with bowel incontinence.
Alkermes has submitted a New Drug Application to the FDA for a novel oral fumarate in development to treat relapsing forms of multiple sclerosis.
Rosalind C. Kalb, PhD, a clinical psychologist, offers her insights on how clinicians can address patient concerns about reproductive issues and MS.
Children with MS were more likely to receive a newer DMT prior to turning 18 years old compared with patients with CIS.
A new warning has been added to the multiple sclerosis drug Lemtrada (alemtuzumab) after rare reports of patients suffering strokes and tears in the lining of the arteries in the head and neck.
Rates of multiple sclerosis relapse decrease during pregnancy but increase postpartum.
The rate and frequency of relapse vary for patients with multiple sclerosis, and many report not visiting a health care provider during relapse.
From September 2010 to February 2018, the FDA has identified 35 cases of severe increased disability accompanied by the presence of new lesions on MRI that occurred 2 to 24 weeks after stopping treatment with fingolimod.
According to a Phase 3b open-label study, Ocrevus may interfere with the effectiveness of non-live vaccines.
Pediatric MS is predominantly inflammatory in nature, with a presentation that is similar to a number of other conditions.
Having a higher burden of comorbidities is associated with greater disability progression and lower QoL, as well as increased healthcare utilization and mortality.
Investigators sought to determine relapse rates of multiple sclerosis decrease prior to pregnancy, during pregnancy, and postpartum.
Investigators propose that myelocortical multiple sclerosis may be a subtype of multiple sclerosis.
Cannabinoids may be mildly effective at treating spasticity, pain, and bladder dysfunction in adults with multiple sclerosis.
Investigators examine the role of physical activity and exercise in the modification of vascular comorbidities and risk factors in individuals with multiple sclerosis.
All participants were smokers or had either diabetes, cancer, depression, cardiovascular, respiratory, thyroid, or gastrointestinal disease and were receiving a DMT.
Natural history data from a subset of patients from the British Columbia MS database between 1980 to 1996 were used to create a continuous Markov model to model the projected course of disease in untreated people with RMS.
Compared with Copaxone injection, treatment with oral Gilenya significantly reduced the annualized relapse rate in patients with relapsing remitting multiple sclerosis.
Researchers categorized samples into quintiles based on 25(OH)D3 concentrations in healthy controls.
Neurology Advisor Articles
- Survival in Parkinson Disease Dependent on Parkinsonian Type, Characteristics
- Migraine History Linked to Increase in All-Cause Dementia Risk
- Case Study Report: Herbal Supplement Kratom Associated With Neonatal Abstinence Syndrome
- Mobile Health Apps for Headache: An Ongoing Search for Clinical Relevancy
- IV Fluid Confers No Significant Treatment Effect on Migraine Pain
- Alemtuzumab Linked to Clinical and MRI Disease Remission in Multiple Sclerosis
- Very Early Mobilization After Stroke Does Not Improve Survival Over Usual Care
- Levodopa Inhalation Powder Approved for Parkinson Disease
- Hematology Indicates Need for Thrombophilia Test in Children With Migraines
- Increased Stroke Risk Following Surgical vs Transfemoral Aortic Valve Replacement
- Ocrelizumab Reduces Upper Extremity Disability Progression Risk in PPMS
- Cerebellar Stimulation May Help Improve Gait and Balance Recovery in Stroke
- Increased Dementia Risk in Older Adults With Down Syndrome
- Psychotherapy May Reduce Frequency of Nonepileptic Seizures
- Should CHA2DS2-VASc Be Reassessed More Frequently to Improve Stroke Prevention in Afib?